Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Is Interim/Mid-Treatment PET (interim PET, i-PET) Scan Predictive of Outcome in Diffuse Large B-Cell Lymphoma?.

Dushyant Verma, MD, FACP, Amol Takalkar, MD, Runhua Shi, MD, PhD, Glenn M. Mills, MD, FACP, Srikanth Paladugu, MD, Diana Veillon, MD, Reinhold Munker, MD, Gerhard Hildebrandt, MD, Binu S. Nair, MD, FACP, Nebu Koshy, MD, FACP

Blood (2012) 120 (21): 2675.

https://doi.org/10.1182/blood.V120.21.2675.2675

Published: 2012

Journal Articles

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

Dushyant Verma, MD, FACP, Kumudha Balakrishnan, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, PhD, Amit Verma, MD, Stefan Faderl, MD, Susan M Bickel, Shanta Bantia, PhD, Hagop M Kantarjian, MD, Michael J. Keating, MBBS, Varsha Gandhi, PhD, Farhad Ravandi, MD

Blood (2009) 114 (22): 2369.

https://doi.org/10.1182/blood.V114.22.2369.2369

Published: 2009

Journal Articles

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Dushyant Verma, MD, FACP, Hagop M Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Amit Verma, MD, Elias Jabbour, MD, Srdan Verstovsek, MD, PhD, Tapan Kadia, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 505.

https://doi.org/10.1182/blood.V114.22.505.505

Published: 2009

Journal Articles

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.

Dushyant Verma, MD, FACP, Hagop M. Kantarjian, MD, Mary Beth Rios, Susan O’Brien, MD, Pat Ault, Elizabeth M. Burton, Zeev Estrov, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Jorge Cortes, MD

Blood (2008) 112 (11): 2125.

https://doi.org/10.1182/blood.V112.11.2125.2125

Published: 2008

Journal Articles

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Dushyant Verma, MD, FACP, Stefan Faderl, MD, Susan O’Brien, MD, Sherry Pierce, Jorge Cortes, MD, Khanh Vu, MD, Emil Freireich, MD, Michael J. Keating, MBBS, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS

Blood (2008) 112 (11): 951.

https://doi.org/10.1182/blood.V112.11.951.951

Published: 2008

Journal Articles

Long-Term Prognostic Impact of the Use of Erythropoiesis-Stimulating Agents (ESA) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib.

Yesid Alvarado, MD, Hagop Kantarjian, MD, Dushyant Verma, MD, Gloria Mattiuzzi, MD, Ahmed Aribi, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 2959.

https://doi.org/10.1182/blood.V110.11.2959.2959

Published: 2007

Journal Articles

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Dushyant Verma, MD, FACP, Deborah Thomas, MD, Susan O’Brien, MD, Stefan Faderl, MD, Charles Koller, MD, Sherry Pierce, RN, Elihu Estey, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2007) 110 (11): 2832.

https://doi.org/10.1182/blood.V110.11.2832.2832

Published: 2007

Journal Articles

Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2 nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure.

Dushyant Verma, MD, FACP, Hagop Kantarjian, MD, Zeev Estrov, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Gautam Borthakur, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 2949.

https://doi.org/10.1182/blood.V110.11.2949.2949

Published: 2007

NARROW

Is Interim/Mid-Treatment PET (interim PET, i-PET) Scan Predictive of Outcome in Diffuse Large B-Cell Lymphoma?.

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Long-Term Prognostic Impact of the Use of Erythropoiesis-Stimulating Agents (ESA) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib.

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2 nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only